Key result
Higher SDNN linked to ~2% greater 90-day mortality risk in acute PE without cancer.
Why the study?
Heart rate variability has been explored as a prognostic index in various cardiovascular conditions, but has received limited investigation regarding pulmonary embolism prognosis.
Do ultra-short heart rate variability indices predict 30-day and 90-day mortality in patients presenting with acute pulmonary embolism?
Cohort (n=233)
No
Do ultra-short heart rate variability indices predict 30-day and 90-day mortality in patients presenting with acute pulmonary embolism?
Ultra-short heart rate variability indices derived from a standard 10-second ECG may offer prognostic value for 90-day mortality in non-oncological patients with acute pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Should not yet change PE risk stratification; hypothesis-generating for ultra-short HRV in non-oncological patients.
Background/Objectives: Pulmonary embolism (PE) remains a significant cause of cardiovascular mortality, with risk stratification being critical for optimizing treatment decisions. Heart rate variability (HRV), a measure of autonomic nervous system function, had been explored as a prognostic index in various cardiovascular conditions, yet has received limited investigation regarding PE prognosis. Our objective was to evaluate the prognostic value of ultra-short HRV indices, obtained at the emergency department (ED), in patients presenting with PE. Methods: A retrospective cohort study, conducted at Rambam Health Care Campus, Haifa, Israel. All eligible patients diagnosed with acute PE at the ED, between the years 2010 and 2012 were included. Further, a subgroup analysis was performed to differentiate between oncological (n = 118) and non-oncological (n = 115) patient populations. Ten-seconds electrocardiogram was used to compute ultra-short HRV indices, specifically SDNN (standard deviation of normal-to-normal RR intervals) and RMSSD (root mean square of successive differences). Multivariate logistic regression models were created to assess HRV’s independent predictive value for 30-day and 90-day mortality. In addition, a survival analysis was carried out utilizing Cox regression and Kaplan-Meier curves. Results: 233 patients (42% male; age 65 ± 17) were included in the analysis. Ultra-short HRV indices did not significantly correlate with short-term mortality. However, in non-oncological patients (n = 115), multivariate analysis demonstrated that higher SDNN (as a continuous variable), was independently associated with increased 90-day mortality (AOR 1.018, 95% CI 1.000–1.037; p = 0.044). In contrast, HRV showed no predictive value for mortality in oncological patients. In both the entire cohort and the non-oncological sub-group, Kaplan-Meier plots established statistically significant differences, with lower HRV indices correlating with worse survival. This finding is paradoxical. The issue of context-dependent HRV (i.e., based on ECG obtained during rapid shallow breathing, which reduces HRV on the one hand, but is possibly adaptive during an acute PE, to increase oxygen supply and prevent shock in the short run, on the other hand), may explain these findings. Conclusions: Ultra-short HRV shows some promise in short term risk stratification of non-oncological PE patients. As for oncological patients, HRV was not found to have short term prognostic relevance.
No takes yet. Share an insight, caveat, or question.
Perek et al. (2026) conducted a cohort in Adults aged 18 and older diagnosed with acute pulmonary embolism presenting to emergency department, including oncological and non-oncological patients (n=233). Ultra-short heart rate variability indices (SDNN and RMSSD) measured from a 10-second ECG at emergency department arrival vs. None (observational assessment of HRV indices correlation to mortality) was evaluated on All-cause mortality at 30 and 90 days after acute pulmonary embolism diagnosis. In non-oncological acute PE patients, higher SDNN was independently associated with increased 90-day mortality (adjusted OR 1.018, 95% CI 1.000–1.037, p = 0.044); HRV showed no predictive value for mortality in oncological patients.
Synapse has enriched 10 related papers. Consider them for comparative context: